Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02HVW
|
|||
| Former ID |
DCL000665
|
|||
| Drug Name |
Zibotentan
|
|||
| Synonyms |
ZD4054; ZD-4054; ZD4054, Zibotentan; Zibotentan (JAN/INN); Trans,trans-2(4-methoxyphenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)pyrrolidine-3-carboxylic acid; N-(3-methoxy-5-methyl-pyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Discontinued in Phase 3 | [1], [2] | |
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H16N6O4S
|
|||
| Canonical SMILES |
CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4
|
|||
| InChI |
1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25)
|
|||
| InChIKey |
FJHHZXWJVIEFGJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 186497-07-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14880486, 24190808, 45981884, 50077277, 68529939, 74721089, 85210245, 87550958, 93310545, 96024464, 99437161, 112379018, 124757263, 124950684, 124966603, 125164067, 125719303, 126651455, 126671547, 127855448, 131480882, 134339186, 135260946, 135368547, 136367429, 136920383, 137025840, 137275851, 141774639, 152048791, 152258082, 152344311, 160646921, 162011975, 162037610, 162202699, 162807569, 177748946, 178100518, 185998560, 196408601, 198974084, 223383997, 223662579, 223705164, 227118911, 242555952, 249582457, 249814523, 252216640
|
|||
| ChEBI ID |
CHEBI:94573
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endothelin A receptor (EDNRA) | Target Info | Antagonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Renin secretion | ||||
| Pathways in cancer | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Endothelin signaling pathway | |||
| Pathway Interaction Database | Endothelins | |||
| EGFR-dependent Endothelin signaling events | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3539). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009560) | |||
| REF 3 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.